Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Massachusetts General Hospital and Harvard Medical School, Boston.
Center for Quantitative Health, Massachusetts General Hospital, Boston.
JAMA Netw Open. 2023 Mar 1;6(3):e234415. doi: 10.1001/jamanetworkopen.2023.4415.
Prior studies using large registries have suggested a modest increase in risk for neurodevelopmental diagnoses among children of mothers with immune activation during pregnancy, and such risk may be sex-specific.
To determine whether in utero exposure to SARS-CoV-2 is associated with sex-specific risk for neurodevelopmental disorders up to 18 months after birth, compared with unexposed offspring born during or prior to the COVID-19 pandemic period.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study included the live offspring of all mothers who delivered between January 1 and December 31, 2018 (born and followed up before the COVID-19 pandemic), between March 1 and December 31, 2019 (born before and followed up during the COVID-19 pandemic), and between March 1, 2020, and May 31, 2021 (born and followed up during the COVID-19 pandemic). Offspring were born at any of 8 hospitals across 2 health systems in Massachusetts.
Polymerase chain reaction evidence of maternal SARS-CoV-2 infection during pregnancy.
Electronic health record documentation of International Statistical Classification of Diseases and Related Health Problems, Tenth Revision diagnostic codes corresponding to neurodevelopmental disorders.
The COVID-19 pandemic cohort included 18 355 live births (9399 boys [51.2%]), including 883 (4.8%) with maternal SARS-CoV-2 positivity during pregnancy. The cohort included 1809 Asian individuals (9.9%), 1635 Black individuals (8.9%), 12 718 White individuals (69.3%), and 1714 individuals (9.3%) who were of other race (American Indian or Alaska Native, Native Hawaiian or other Pacific Islander, more than 1 race); 2617 individuals (14.3%) were of Hispanic ethnicity. Mean maternal age was 33.0 (IQR, 30.0-36.0) years. In adjusted regression models accounting for race, ethnicity, insurance status, hospital type (academic center vs community), maternal age, and preterm status, maternal SARS-CoV-2 positivity was associated with a statistically significant elevation in risk for neurodevelopmental diagnoses at 12 months among male offspring (adjusted OR, 1.94 [95% CI 1.12-3.17]; P = .01) but not female offspring (adjusted OR, 0.89 [95% CI, 0.39-1.76]; P = .77). Similar effects were identified using matched analyses in lieu of regression. At 18 months, more modest effects were observed in male offspring (adjusted OR, 1.42 [95% CI, 0.92-2.11]; P = .10).
In this cohort study of offspring with SARS-CoV-2 exposure in utero, such exposure was associated with greater magnitude of risk for neurodevelopmental diagnoses among male offspring at 12 months following birth. As with prior studies of maternal infection, substantially larger cohorts and longer follow-up will be required to reliably estimate or refute risk.
先前使用大型注册研究表明,母亲在怀孕期间免疫激活会使儿童患神经发育障碍的风险略有增加,而且这种风险可能具有性别特异性。
确定与未暴露于 SARS-CoV-2 的后代相比,在 COVID-19 大流行期间或之前出生并在出生后 18 个月内,子宫内暴露于 SARS-CoV-2 是否与神经发育障碍的特定性别风险相关。
设计、地点和参与者:这项回顾性队列研究纳入了所有于 2018 年 1 月 1 日至 12 月 31 日(出生并在 COVID-19 大流行前随访)、2019 年 3 月 1 日至 12 月 31 日(出生前并在 COVID-19 大流行期间随访)和 2020 年 3 月 1 日至 2021 年 5 月 31 日(出生和在 COVID-19 大流行期间随访)期间分娩的所有母亲的活产儿。这些活产儿出生于马萨诸塞州 2 个卫生系统的 8 家医院。
妊娠期间母亲 SARS-CoV-2 感染的聚合酶链反应证据。
电子健康记录中与神经发育障碍相对应的国际疾病分类和相关健康问题第十次修订诊断代码。
COVID-19 大流行队列包括 18355 例活产儿(9399 名男孩[51.2%]),其中 883 例(4.8%)母亲在怀孕期间 SARS-CoV-2 呈阳性。该队列包括 1809 名亚洲个体(9.9%)、1635 名黑人个体(8.9%)、12718 名白人个体(69.3%)和 1714 名其他种族(美洲印第安人或阿拉斯加原住民、夏威夷原住民或其他太平洋岛民、多种族)个体(9.3%);2617 名个体(14.3%)具有西班牙裔血统。母亲的平均年龄为 33.0(IQR,30.0-36.0)岁。在调整了种族、民族、保险状况、医院类型(学术中心与社区)、母亲年龄和早产状况后,在回归模型中,母亲 SARS-CoV-2 阳性与男性后代 12 个月时神经发育诊断风险显著升高相关(调整后的 OR,1.94[95%CI,1.12-3.17];P=0.01),但与女性后代无关(调整后的 OR,0.89[95%CI,0.39-1.76];P=0.77)。使用回归分析代替匹配分析也可以得到类似的效果。在 18 个月时,男性后代的影响更为适度(调整后的 OR,1.42[95%CI,0.92-2.11];P=0.10)。
在这项对子宫内接触 SARS-CoV-2 的后代的队列研究中,这种接触与男性后代在出生后 12 个月时神经发育诊断的风险增加具有更大的相关性。与之前的母体感染研究一样,需要更大的队列和更长时间的随访,才能可靠地估计或反驳风险。